A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 46-52

  Zurita, A J ^a   Jonasch, E ^a   Wang, X ^a   Khajavi, M ^a   Yan, S ^a   Du, D Z ^a   Xu, L ^a   Herynk, M H ^a   Mckee, K S ^a   Tran, H T ^a   Logothetis, C J ^a   Tannir, N M ^a   Heymach, J V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CAF profiling; Interferon; RCC combinations; Renal cell carcinoma; Sorafenib

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENIC FACTOR; CARBONATE DEHYDRATASE IX; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CLUSTER ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CHOICE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 84855173597     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr047     Document Type: Article

References (36)

1. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
3. Nickerson ML, Jaeger E, Shi Y et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726-4734.
4. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318.
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
7. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
8. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
9. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
10. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
11. Dosquet C, Coudert MC, Lepage E et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3: 2451-2458.
12. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163: 343-347.
13. Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004; 22: 2371-2378.
14. Negrier S, Chabaud S, Escudier B et al. Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007; 25: 5044.
15. Pena C, Lathia C, Shan M et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010; 16: 4853-4863.
16. Escudier BJ, Ravaud A, Négrier S et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol 2008; 26: 15S (Abstr 5025).
17. Zurita AJ, Jonasch E, Wu HK et al. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 2009; 115: 2346-2354.
18. Hanrahan EO, Lin HY, Kim ES et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 193-201.
19. Jonasch E, Corn P, Pagliaro LC et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116: 57-65.
20. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
21. Ebos JM, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
22. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
23. McAllister SS, Gifford AM, Greiner AL et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.
24. Tannir NM, Cohen L, Wang X et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferonalpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2254-2261.
25. Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476.
26. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
27. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
28. Hanrahan EO, Ryan AJ, Mann H et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in nonsmall cell lung cancer. Clin Cancer Res 2009; 15: 3600-3609.
29. Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007; 25: 18S (Abstr 5023).
30. Deprimo SE, Bello CL, Smeraglia J et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5: 32.
31. Hutson TE, Davis ID, Machiels JH et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008; 26: 15S (Abstr 5046).
32. Rixe O, Meric J, Bloch J et al. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23: 16S (Abstr 3003).
33. van Herpen C, Drevs J, van Cruijsen H et al. Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): combined results from two phase I studies. J Clin Oncol 2007; 25: 18S (Abstr 3560).
34. Montero AJ, Diaz-Montero CM, Millikan RE et al. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferonalpha: association of pretreatment serum levels with survival. Ann Oncol 2009; 20: 1682-1687.
35. Perez-Gracia JL, Prior C, Guillen-Grima F et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009; 101: 1876-1883.
36. Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70: 1063-1071.